Granted Patent
B2
US 12,697,343 · App. 18/273,143 · Granted Aug 4, 2026
Intravenous istaroxime for the treatment of acute heart failure
Inventors:
Giuseppe Bianchi (Milan, IT); Patrizia Ferrari (Varese, IT); Mara Ferrandi (Milan, IT); Paolo Barassi (Castelveccana, IT)
Assignee:
Seismic Pharmaceuticals Operations LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are methods of treating acute heart failure in a subject in need thereof, comprising administering a therapeutically effective amount of istaroxime by intravenous infusion over a period of at least 24 hours wherein the therapeutically effective amount of istaroxime is between about 0.1 μg/kg/min and about 3.0 g/kg/min; and wherein the subject's acute heart failure is treated.
Claims (22)
1 . A method of treating acute heart failure in a subject in need thereof, comprising administering a therapeutically effective amount of istaroxime by intravenous infusion over a period of at least 24 hours, wherein the therapeutically effective amount of istaroxime is between about 0.1 μg/kg/min and about 3.0 μg/kg/min, wherein administering a therapeutically effective amount of istaroxime does not result in a significant change in at least one of heart rate, myocardial energy consumption, brain natriuretic peptide (BNP) levels, N-terminal pro BNP (NT-proBNP) levels, and cardiac troponin levels, thereby treating the subject's acute heart failure.
2 . The method of claim 1 , wherein the subject has at least one of low cardiac output, hypotension, low systolic blood pressure, reduced left ventricular ejection fraction, intermediate to high E/e′ ratio, a resting heart rate between about 50 and about 120 beats per minute, a potassium level between about 3.8 and about 5.3 mmol/L, and a serum creatinine level greater than 3.0 mg/dL or an estimated glomerular filtration rate (eGFR) greater than 30 mL/min/m 2 prior to administrating a therapeutically effective amount of istaroxime.
3 . The method of claim 1 , wherein the subject is hospitalized for acute heart failure, prior to administering a therapeutically effective amount of istaroxime.
4 . The method of claim 1 , wherein the subject:
(i) is not receiving concomitant treatment with intravenous vasodilators, inotropes, vasopressors, oral digoxin or any combination thereof prior to administering a therapeutically effective amount of istaroxime;
(ii) is resistant to diuretics, vasodilators, or a combination thereof; or
(iii) both (i) and (ii).
5 . The method of claim 1 , wherein administering a therapeutically effective amount of istaroxime results in a decreased heart rate, an increase in systolic blood pressure, or both.
6 . The method of claim 1 , wherein administering a therapeutically effective amount of istaroxime results in a decreased heart rate by about 3 to about 9 beats per minute.
7 . The method of claim 1 , wherein administering a therapeutically effective amount of istaroxime results in an increase in systolic blood pressure by about 15 mmHg.
8 . The method of claim 1 , wherein administering a therapeutically effective amount of istaroxime results in an increase in systolic blood pressure by about 3 to about 8 mmHg.
9 . The method of claim 1 , wherein administering a therapeutically effective amount of istaroxime results in an improvement in cardiac function without tachycardia or hypotension.
10 . The method of claim 1 , wherein administering a therapeutically effective amount of istaroxime results in at least one of increased cardiac contractility, increased myocardial relaxation, increased ventricle relaxation, increased rate of myocardial relaxation, increased inotropy, increased left ventricular systolic function, increased stroke volume index, increased afterload associated with decreased E′no “, increased renal function, increased organ reperfusion, increased left ventricular ejection fraction, and increased diuresis.
11 . The method of claim 1 , wherein administering a therapeutically effective amount of istaroxime results in an increase in renal function.
12 . The method of claim 1 , wherein administering a therapeutically effective amount of istaroxime does not result in at least one of major cardiac adverse events, myocardial ischemia, hypotension, tachycardia, arrhythmias, end organ damage, and increased mortality.
13 . The method of claim 1 , wherein administering a therapeutically effective amount of istaroxime results in an improvement in cardiac function without end organ damage.
14 . The method of claim 1 , wherein treatment is observable for up to 48 hours.
15 . The method of claim 3 , wherein administering a therapeutically effective amount of istaroxime results in a decreased risk of readmissions or emergency visits for cardiovascular reasons for at least 30 days after administration, a reduced risk of episodes of in-hospital worsening heart failure for at least 4 days after administration, or both.
16 . The method of claim 1 , further comprising a downward titration of istaroxime following intravenous infusion over a period of at least 24 hours.
17 . The method of claim 1 , further comprising administering a diuretic.
18 . The method of claim 1 further comprising administering at least 20 mg intravenous furosemide.
19 . The method of claim 1 , further comprising administering an antiemetic if the subject experiences gastrointestinal upset.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 28, 2026
From: WINDTREE THERAPEUTICS INC.
To: SEISMIC PHARMACEUTICALS
Reel/Frame 073612/0152 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 28, 2026
From: SEISMIC PHARMACEUTICALS INC.
To: SEISMIC PHARMACEUTICALS OPERATIONS LLC
Reel/Frame 073612/0258 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 28, 2026
From: SEISMIC PHARMACEUTICALS INC.
To: SEISMIC PHARMACEUTICALS OPERATIONS LLC
Reel/Frame 073612/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 24, 2025
From: WINDTREE THERAPEUTICS INC.
To: SEISMIC PHARMACEUTICALS
Reel/Frame 073018/0285 →
Continuity (2)
Provisional Application
63140552
· Jan 22, 2021
Related Publication
20240293426A1
· Sep 5, 2024
References Cited (148)
US 4534899A
· Sears
· 1985
[cited by applicant]
US 5846743A
· Janmey et al.
· 1998
[cited by applicant]
US 5874268A
· Meyer
· 1999
[cited by applicant]
US 6007839A
· Mayhew et al.
· 1999
[cited by applicant]
US 6063400A
· Geho et al.
· 2000
[cited by applicant]
US 6261815B1
· Meyer
· 2001
[cited by applicant]
US 6384250B2
· Gobbini
· 2002
[cited by applicant]
US 6589503B1
· Piwnica-Worms
· 2003
[cited by applicant]
US 7109034B2
· Orwar et al.
· 2006
[cited by applicant]
US 7306783B2
· Piwnica-Worms
· 2007
[cited by applicant]
US 20040028670A1
· Carlson et al.
· 2004
[cited by applicant]
US 20040151766A1
· Monshan et al.
· 2004
[cited by applicant]
US 20050136121A1
· Kershman et al.
· 2005
[cited by applicant]
US 20070077286A1
· Ishihara et al.
· 2007
[cited by applicant]
US 20070082042A1
· Park et al.
· 2007
[cited by applicant]
US 20070110788A1
· Drummond et al.
· 2007
[cited by applicant]
US 20110097401A1
· Phillips et al.
· 2011
[cited by applicant]
CN 103315968B
· 2016
[cited by applicant]
EP 0826197B1
· 1998
[cited by applicant]
WO WO2010149666A1
· 2010
[cited by applicant]
WO WO2020180356A9
· 2020
[cited by applicant]
Carubelli et al. European Journal of Heart Failure, 2020, 22(9): 1684-1693.
[cited by examiner]
Abraham et al., “In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (Adhere)” …
[cited by applicant]
Alemanni et al. “Role and mechanism of subcellular Ca2+ distribution in the action of two inotropic agents with different toxicity” J Mol Cell Cardiol 50:910-8 (2011).
[cited by applicant]
Al-Muhammed, “In-vivo studies on dexamethasone sodium phosphate liposomes” J. Microencapsul. 13:293-306 (1996).
[cited by applicant]
Asahi et al., “Transmembrane helix M6 in sarco(endo)plasmic reticulum Ca(2+)-ATPase forms a functional interaction site with phospholamban. Evidence for physical interactions at other sites” J Biol Chem 274: 32855-32862…
[cited by applicant]
Ashkar & Makaryus, “Dobutamine”, In StatPearls [Internet], Treasure Island (FL): StatPearls Publishing, Jan. 2017-2018 (available at https://www.ncbi.nlm.nih.gov/books/NBK470431/).
[cited by applicant]
Baheti et al., “Excipients used in lyophilization of small molecules” J. Excipients and Food Chem. 1(1):41-54 (2010).
[cited by applicant]
Bers et al., “Regulation of Ca2+ and Na+ in normal and failing cardiac myocytes” Ann N.Y. Acad Sci 2006; 1080:165-177 (2006).
[cited by applicant]
Bers, “Altered cardiac myocyte Ca regulation in heart failure” Physiology 21: 380-387 (2006).
[cited by applicant]
Bers, “Calcium cycling and signaling in cardiac myocytes” Annu Rev Physiol 70:23-49 (2008).
[cited by applicant]
Braunwald, “The war against heart failure: the Lancet lecture” 2015; 385:812-24 (2015).
[cited by applicant]
Brophy et al., “Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients” Eur. J. Clin. Pharmacol. 24:103-108 (1983).
[cited by applicant]
Bonsu el al., “Pharmacological treatments for heart failure with preserved ejection fraction—a systematic review and indirect comparison” Heart Failure Reviews 23:147-156 (2018).
[cited by applicant]
Butler et al., “Past, present, and future of acute heart failure clinical trials—a high-risk population in search of a strategy” Eur J Heart Fail.20(5):839-841 (2018).
[cited by applicant]
Byrne et al., “Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals” Gene Therapy 15:1550-1557 (2008).
[cited by applicant]
Campia et al. “Acute Heart Failure with Low Cardia Output: Can We Develop a Short-term Inotropic Agent that Does Not Increase Adverse Events?” Curr, Heart Fall. Rep. 7:100-109 (2010).
[cited by applicant]
Carillion et al., “Atorvastatin reduces β-Adrenergic dysfunction in rats with diabetic cardiomyopathy” PloS One e0180103 (2017).
[cited by applicant]
Choi et al., “Defective intracellular Ca2+ signaling contributes to cardiomyopathy in Type 1 diabetic rats” Am. J. Physiol. Heart Cir. Physiol 283:H1398-H1408 Sep. 2002).
[cited by applicant]
Chonn & Cullis, “Recent advances in liposomal drug-delivery systems” Curr. Opin. Biotechnol. 6:698-708 (1995).
[cited by applicant]
De Munari et al., “Structure-based design and synthesis of novel potent Na+, K+-ATPase inhibitors derived from a 5alpha,14alpha-androstane scaffold as positive inotropic compounds” J. Med. Chem. 46(17): 3644-3654 (2003).
[cited by applicant]
Do Carmo et al., “Chronic central leptin infusion restores cardiac sympathetic-vagal balance and baroreflex sensitivity in diabetic rats” Am. J. Physiol. Heart Cir. Physiol 295:H1974-1981 (2008).
[cited by applicant]
Evangelista et al., “European Association of Echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies” Eur J Echocardiogr 9(4):438-48 (2008).
[cited by applicant]
Fernandez-Tenorío & Niggli, “Stabilization of Ca 2+ signaling in cardiac muscle by stimulation of SERCA” J Mol Cell Cardiol. 119:87-95 (2018).
[cited by applicant]
Ferrandi et al., “Renal Na,K-ATPase in genetic hypertension” Hypertension 28(6):1018-25 (1996).
[cited by applicant]
Ferrandi et al., “Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition” Br J Pharmacol 169:1849-61 (2013).
[cited by applicant]
Flaherty et al., “Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment” J Am Coll Cardiol. 53(3):254-63 (2009).
[cited by applicant]
Fotherby, “Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy” Contraception 54:59-69 (1996).
[cited by applicant]
Georghiade et al., “Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent” J Am Coll Cardiol.51:2276-85 (2008).
[cited by applicant]
Ghio et al., “Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure” J Am Coll Cardiol 37(1):183-8 (2001).
[cited by applicant]
Gong et al., “Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis” J Cardiothorac Vasc Anesth 29:1415-25 (2015).
[cited by applicant]
Größl et al., “A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca2+ uptake into the sarcoplasmic reticulum” PLoS One 9:e92188 (2014).
[cited by applicant]
Guido et al., “The Effects of Diabetes Induction on the Rat Heart: Differences in Oxidative Stress, Inflammatory Cells, and Fibrosis between Subendocardial and Interstitial Myocardial Areas” Oxid Med Cell Longev.2017: 5…
[cited by applicant]
Gulati et al., “Mitral annular descent velocity by tissue Doppler echocardiography as an index of global left ventricular function” Am J Cardiol. 77(11):979-84 (1996).
[cited by applicant]
Haddad et al., “Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure” Circulation 117(13):1717-31 (2008).
[cited by applicant]
Heineke & Molkentin, “Regulation of cardiac hypertrophy by intracellular signalling pathways” Nat Rev 7:589-600 (2006).
[cited by applicant]
Hidalgo-Aragones et al., “Pharmacokinetics of oestrone-3-O-sulphamate” Steroid Biochem. Mol. Biol. 58:611-617 (1996).
[cited by applicant]
Hoshijima et al., “Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery” Nat. Med. 8:864-871 (2002).
[cited by applicant]
Hougen & Friedman, “Age-related effects of digoxin on myocardial contractility and Na-K pump in sheep” Am J Physiol. 243(4):H517-22 (1982).
[cited by applicant]
Hulot et al., “Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial” Eur Heart J 19:1534-…
[cited by applicant]
Iwanaga et al., “Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats” J Clin Invest 113, 727-736 (2004).
[cited by applicant]
Joffe et al., “Abnormal cardiac function in the streptozolocin-induced non-insulin-dependent diabetic rat: noninvasive assessment with doppler echocardiography and contribution of the nitric oxide pathway” JACC 34(7):21…
[cited by applicant]
Johnson et al. “Permeation of steroids through human skin” J. Pharm. Sci. 84:1144-1146 (1995).
[cited by applicant]
Jørgensen, “Purification of Na+,K+-ATPase: enzyme sources, preparative problems, and preparation from mammalian kidney” Methods Enzymol. 156:29-43 (1988).
[cited by applicant]
Kaneko et al., “A pyridone derivative activates SERCA2a by attenuating the inhibitory effect of phospholamban” Eur J Pharmacol 814:1-7 (2017).
[cited by applicant]
Karim et al., “Phosphorylation-dependent conformational switch in spin-labeled phospholamban bound to SERCA” J Mol Biol 358:1032-1040 (2006).
[cited by applicant]
Kaye et al., “Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals” J. Am. Coll. Cardiol. 50:253-260 (2007).
[cited by applicant]
Lancellotti et al., “European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease)” Eur J Echocardiogr 11(4):307…
[cited by applicant]
Lang et al., “Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Commillee and the Chamber Quantification Writing Group, developed in conjunctio…
[cited by applicant]
Lipskaya et al., “Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure” Expert Opin Biol Ther 10:29-41 (2010).
[cited by applicant]
Lloyd-Jones et al., “Lifetime risk for developing congestive heart failure: the Framingham Heart Study” Circulation 106:3068-3072 (2002).
[cited by applicant]
Lohse et al., “What is the role of beta-adrenergic signaling in heart failure?” Circ Res 93:896-906 (2003).
[cited by applicant]
Luciani et al., “Development and physico-chemical characterization of a liposomal formulation of istaroxime” Eur J Pharm Biopharm. 79(2):285-93 (2011).
[cited by applicant]
MacLennan & Kranias, “Phospholamban: a crucial regulator of cardiac contractility” Nat Rev Mol Cell Biol 4(7):566-577 (2003).
[cited by applicant]
Mann & Bristow, “Mechanisms and models in heart failure: the biomechanical model and beyond” Circulation 111:2837-2849 (2005).
[cited by applicant]
Mattera et al., “Istaroxime: a new luso-inotropic agent for heart failure” Am J Cardiol 99(2A):33A-40A (2007).
[cited by applicant]
Metra & Teerlink, “Heart failure” Lancet 390:1981-1995 (2017).
[cited by applicant]
Micheletti et al., “Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744)” J Pharmacol Exp Ther 303:592-600 (2002).
[cited by applicant]
Micheletti et al., “Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure” Am J Card 99(2A):24A-32A (2007).
[cited by applicant]
Mihm et al., “Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model” Life Sci. 69(5):527-42 (2001).
[cited by applicant]
Minamisawa et al., “Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy” Cell 99:313-322 (1999).
[cited by applicant]
Mitter et al., “A Test in Context: E/A and E/e′ to Assess Diastolic Dysfunction and LV Filling Pressure” JACC 69(11):1451-1464 (2017).
[cited by applicant]
Nagueh et al., “Recommendations for the evaluation of left ventricular diastolic function by echocardiography” Eur J Echocardiogr 10(2):165-93 (2009).
[cited by applicant]
Nakayama et al., “Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure” J Clin Invest 117:2431-44 (2007).
[cited by applicant]
Nediani et al., “Stimulation of cardiac sarcoplasmic reticulum calcium pump by acylphosphatase. Relationship to phospholamban phosphorylation” J Biol Chem. 271:19066-73 (1996).
[cited by applicant]
Nicholson & Turner, “Marine steroids. Part III. On the structure of marthasterone glucoside, from the starfish
[cited by applicant]
No Author listed, “An Account of the Effects of the Digitalis Purpurea in Dropsy” Lond Med J. 6(Pt 1):55-60 (1785).
[cited by applicant]
Ostro & Cullis, “Use of liposomes as injectable-drug delivery systems” Am. J. Hosp. Pharm. 46:1576-1587 (1989).
[cited by applicant]
Packer, “The Room Where It Happens: A Skeptic's Analysis of the New Heart Failure Guidelines” J. Card. Fail. 22:726-730 (2016).
[cited by applicant]
Packer, “Why is the use of digitalis withering? Another reason that we need medical heart failure specialists” Eur J Heart Failure 20:851-852 (2018).
[cited by applicant]
Patel et al., “Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF” Circ Heart Failure 7:918-925 (2014).
[cited by applicant]
Pellicori et al., “IVC diameter in patients with chronic heart failure: relationships and prognostic significance” JACC Cardiovasc Imaging 6(1):16-28 (2013).
[cited by applicant]
Pinz et al., “Comprimised myocardial energetics in hypertrophied mouse hearts diminish the beneficial effect of overexpressing SERCA2a” J Biol Chem 286(12):10163-10168 (2011).
[cited by applicant]
Revill et al., “Isaroxime” in Drugs of the Future 32(7):595-600 (2007).
[cited by applicant]
Rigopoulus et al., “Acute heart failure. An unmet medical need” Herz44:53-55 (Epub Sep. 22, 2017).
[cited by applicant]
Rocchetti et al., “Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride]” J Pharmacol Ex…
[cited by applicant]
Sabbah et al., “A canine model of chronic heart failure produced by multiple sequential coronary microembolizations” Am J Physiol. 260:H1379-84 (1991).
[cited by applicant]
Sabbah et al., “Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure” Am J Cardiol. 99(2A):41A-46A (2007).
[cited by applicant]
Sato et al., “Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation” J Biol Chem 276:9392-99 (2001).
[cited by applicant]
Schwinger et al., “Reduced Ca(2+)-sensitivity of SERCA 2a in falling human myocardium due to reduced serin-16 phospholamban phosphorylation” J Mol Cell Cardiol. 31(3):479-91 (1999).
[cited by applicant]
Seidler et al., “Cyclopiazonic acid is a specific inhibitor of the Ca2+-ATPase of sarcoplasmic reticulum” J Biol Chem. 264:17816-23 (1989).
[cited by applicant]
Shah et al., “Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lu…
[cited by applicant]
Shattock et al., “Na+/Ca2+ exchange and Na+/K+-ATPase in the heart” J Physiol. 15;593(6):1361-82 (2015).
[cited by applicant]
Solomon et al., “Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure” Circulation 116(13):1482-87 (2007).
[cited by applicant]
Tamargo et al. “Investigational Positive Inotropic Agents for Acute Heart Failure” Cardiovasc, & Haematolog, Disorders—Drug Targets 9:193-205 (2009).
[cited by applicant]
Teerlink et al., “Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study” J Am Coll Cardiol.67(12):1444-1455 (2016).
[cited by applicant]
Teneggi et al., “Drugs' development in acute heart failure: what went wrong?” Heart Failure Rev 23:667-691 (2018).
[cited by applicant]
ThackerayJT et al., “Sympathetic nervous dysregulation in the absence of systolic left ventricular dysfunction in a rat model of insulin resistance with hyperglycemia” Cardiovasc Diabetol.10(75):1-13 (2011).
[cited by applicant]
Toyoshima et al., “Modeling of the inhibitory interaction of phospholamban with the Ca2+ ATPase” Proc Natl Acad Sci USA 100:467-47 (2003).
[cited by applicant]
Ventura-Clapier et al., “Bloenergetics of the failing heart” Biochim Biophys Acta. 1813(7):1360-72 (2011).
[cited by applicant]
Voelkel et al., “Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure” Circulation 114(17):1883-91 (2006…
[cited by applicant]
Whitbeck et al., “Increased mortality among patients taking digoxin—analysis from the AFFIRM study” Eur Heart J. 34(20):1481-8 (2013).
[cited by applicant]
Zaza & Rocchetti, “Calcium store stability as an antiarrhythmic endpoint” Curr Pharm Des 21:1053-1061 (2015).
[cited by applicant]
Adamson et al., “Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure” J Cardiovasc Pharmacol 42:169-173 (2003).
[cited by applicant]
Ambrosy et al., “The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries” J Am Coll Cardiol 63:1123-1133 (2014).
[cited by applicant]
Blair et al., “Rationale and Design of the Hemodynamic, Echocardiographic and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Controlled Trial in Patients Hospitaliz…
[cited by applicant]
Butler et al., “In-hospital worsening heart failure” Eur J Heart Fail 17:1104-1113 (2015).
[cited by applicant]
Carubelli et al., “Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomized, placebo-controlled trial” Eur J Heart Fail 22:1684-1693 (2020).
[cited by applicant]
Chioncel et al., “Natriuretic peptide-guided management in heart failure” J Cardiovasc Med 17:556-568 (2016).
[cited by applicant]
Chioncel et al., “ESC Heart Failure Long-Term Registry Investigators, Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry” Eur J Heart Fail 19:1242-…
[cited by applicant]
Chioncel et al., “ESC-EORP-HFA Heart Failure Long-Term Registry Investigators. Acute heart failure congestion and perfusion status—impact of the clinical classification on in-hospital and long-term outcomes; insights fr…
[cited by applicant]
Chioncel et al., “Istaroxime in acute heart failure: the holy grail is at Horizon?” Eur J Heart Fail. 22(9):1694-1697 (2020).
[cited by applicant]
Database Registry, Compound Registration No. 744195-06-0 (Sep. 14, 2004).
[cited by applicant]
Felker et al., “Heart failure etiology and response to Milrinone in decompensated heart failure. Results from the OPTIME-CHF study” Heart Failure 41(6):997-1003 (2003).
[cited by applicant]
Gheorghiade et al., “OPTIMIZE-HF Investigators and Coordinators, Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure” JAMA 296:2217-2226 (2006).
[cited by applicant]
Gheorghiade & Sabbah, “Istaroxime: an investigational luso-inotropic agent for acute heart failure syndromes.” Am J Cardiol 99:1A-3A (2007).
[cited by applicant]
Gheorghiade et al., “Combining SERCA2a activation and Na—K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output” Discov Med 12:141-151 (2011).
[cited by applicant]
Gheorghiade et al., “Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure” Heart Fail Rev 18:107-122 (2013).
[cited by applicant]
Hamo et al., “The bumpy road to drug development for acute heart failure” Eur Heart J Suppl 18(Suppl G):G19-G32 (2016).
[cited by applicant]
Harjola et al., “Organ dysfunction, Injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (…
[cited by applicant]
Hasenfuss & Teerlink, “Cardiac inotropes: current agents and future directions” Eur Heart J 32:1838-1845 (2011).
[cited by applicant]
Khan et al., “Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na—K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?” Heart Fail Rev 14:277-287 (2009).
[cited by applicant]
Maack et al., “Treatments targeting inotropy” Eur Heart J 40:3626-3644 (2019).
[cited by applicant]
Mebazaa et al., “Levosimendan vs Dobutamine for patients with acute decompensated heart failure. The survive randomized trial” JAMA 297:1883-1891 (2007).
[cited by applicant]
Mebazaa et al., “Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Em…
[cited by applicant]
Mebazaa et al., “ESC Heart Failure Long-Term Registry Investigators. Long-term safety of Intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term …
[cited by applicant]
Metra et al., “Old and new intravenous inotropic agents in the treatment of advanced heart failure” Prog Cardiovasc Dis 54:97-106 (2011).
[cited by applicant]
Ponikowski et al., “ESC guidelines for the diagnosis and treatment of acute and chronic heart fallure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiol…
[cited by applicant]
Psotka et al. “Cardiac calcitropes, myotropes, and mitotropes: JACC review topic of the week” J Am Coll Cardiol 73:2345-2353 (2019).
[cited by applicant]
Teerlink et al., “Agents with inotropic properties for the management of acute heartfailure syndromes. Traditional agents and beyond” Heart Fall Rev 14: 243-253 (2009).
[cited by applicant]
Thackray et al., “The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis.” Eur J Heart Fail 4:515-529 …
[cited by applicant]
Yancy et al., “ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines” Circulati…
[cited by applicant]
International Search Report and Written Opinion in international patent application No. PCT/US2022/013278 mailed Apr. 7, 2022.
[cited by applicant]